ARTIVION INC ($NYSE:AORT) released their Q2 results for Fiscal Year 2023 on August 3, 2023 – showing total revenue of USD 89.2 million, an 11.1% increase from FY2022. Unfortunately, net income decreased year-over-year from -4.3 million to -3.4 million.
ARTIVION INC announced its financial results for the second quarter of fiscal year 2023 ended June 30, 2023 on Thursday. The company’s stock opened at $17.0 and closed at $16.8, a decrease of 1.7% from the prior closing price of 17.1. This marks a significant decrease in stock value when compared to the same period the previous year.
Overall, ARTIVION INC reported mixed financial results for the second quarter of fiscal year 2023. The company’s stock decreased significantly from the prior closing price, but net income decreased only slightly and total assets increased significantly. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Artivion Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Artivion Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Artivion Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Artivion Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we conducted an analysis of ARTIVION INC‘s fundamentals, and based on our Star Chart, ARTIVION INC is strong in growth, medium in profitability and weak in assets and dividend. The health score of ARTIVION INC is an intermediate 5/10 considering its cashflows and debt. We believe it might be able to pay off debt and fund future operations. We classified ARTIVION INC as a ‘rhino’ company, which has achieved moderate revenue or earnings growth. Investors who are interested in moderate but steady returns are likely to want to invest in a company like ARTIVION INC. More…
Risk Rating Analysis
Star Chart Analysis
The company has a strong market presence in Europe and North America. Artivion Inc competes with BICO Group AB, IVF Hartmann Holding AG, and Bioventus Inc. in the global IVF market.
BICO Group AB is a Swedish company that provides healthcare and hygiene products. The company has a market cap of 215.89M as of 2022 and a Return on Equity of 0.14%. BICO Group AB’s products include medical gloves, face masks, and disinfectants. The company’s products are used in hospitals, clinics, and by consumers.
– IVF hartmann Holding AG ($LTS:0QQM)
As of 2022, hartmann Holding AG has a market cap of 268.8M and a Return on Equity of 4.11%. The company is engaged in the production of medical and hygiene products.
Bioventus Inc is a medical device company that focuses on the development and commercialization of products for the orthopedic market. The company has a market cap of 423.63M as of 2022 and a Return on Equity of -5.08%. Bioventus was founded in 2006 and is headquartered in Durham, NC.
Investors looking at ARTIVION INC’s FY2023 Q2 earnings results should be encouraged by the 11.1% year over year increase in total revenue to USD 89.2 million. Unfortunately, the company’s net income decreased from -4.3 million to -3.4 million. Nevertheless, investors should look at other factors such as cash flow, debt levels, and other financial metrics to determine if there is potential for long-term growth and returns. Analyzing its financial health and performance, such as its operating margin, and assessing its competitive position in the industry should be key elements to a successful investment decision.